Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio.

A new report compiles the latest data and insight on scaling cell and gene therapy (CGT) effectively to improve patient access.

BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation.

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.

Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.

Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent’s success pushed Sanofi’s total net sales to €9.9bn, up 10% at ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

MetrioPharm’s lead compound, MP1032, has received ODD from the European Medicines Agency (EMA) for treating DMD in children.

Viridian and Kissei Pharmaceutical have signed an exclusive partnership and license agreement for advancing veligrotug and VRDN-003.

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.